knowledge -WSS

knowledge

author：knowledge 2025-08-23 18:38:05 - browse：94

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Change Healthcare payments predicted restored March 15

knowledge

WSS

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Air quality improving but still lags in Black, Hispanic communities

The problem with charging patients to message their doctors

Leqembi, other new Alzheimer’s drugs require better biomarkers

NEJM study link tiny plastics in blood vessels to heart problems

Study: Pain burden is higher in Black NFL players than white ones

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Sen. Paul opposes bill to ban Chinese biotechs

Hepatitis C has a cure — but many Americans still lack access to it

Former medical device CEO who sold dummy, plastic parts convicted of fraud

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

The cancer drug shortage isn’t new — and neither are the solutions

Why 40% Americans with Parkinson’s don’t see a neurologist

Apple is now the first public company to be valued at $3 trillion

A deep dive into Applied Therapeutics’ data, and questions on Cassava

leisure time

With psoriasis trial ahead, Alumis raises $259 million

Lecanemab for Alzheimer's is coming. Is the health system ready?

The drug industry has found itself all alone in Washington

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Change Healthcare payments predicted restored March 15

How the political right came to back psychedelics to treat trauma

hotspot

knowledge

Wikipedia

hotspot